100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44DK110972
Award Date
9/1/16
Completion Date
8/31/21
Dollars Obligated
$1.3M
Overview
Activity
9
Transactions
9
Subawards
Similar Awards
Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Awardee
SFC Fluidics, Inc. (GTPCCLD8LK26)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Arkansas, USA
Update #1
Update #2
DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR
Posted 9/19/18
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR - DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR PROJECT SUMMARY: THE SPECIFIC AIM OF THIS PROJECT IS TO DEVELOP A DISCRETE, LOW-PROFILE, DUAL HORMONE DRUG DELIVERY SYSTEM USING SFC FLUIDICS' ENABLING MICROFLUIDIC TECHNOLOGIES. A DUALPUMP WILL BE DEVELOPED IN WHICH ONE PROPRIETARY EPUMP BODY WILL INDEPENDENTLY AND ACCURATELY DELIVER BOTH INSULIN AND GLUCAGON FROM TWO SEPARATE RESERVOIRS. LATCHING SAFETY VALVE SETS WILL INDEPENDENTLY AND SAFELY CONTROL THE DELIVERY OF EACH HORMONE AND A DISPENSE CONFIRMATION SENSOR WILL NOTIFY THE USER OF ANY DOSING ERRORS RESULTING FROM OCCLUSIONS OR ELECTRICAL/MECHANICAL FAILURES. PHASE II WILL SEE THE INTEGRATION OF ALL COMPONENTS INTO AN ACCURATE, DISCRETE, LOW-PROFILE WEARABLE POD, EXTENSIVE BENCHTOP TESTING AND INITIAL TESTING IN SWINE. THE END GOAL OF PHASE II IS PRODUCTION OF A DUALPUMP MODULE THAT HAS BEEN INTRODUCED TO THE FDA AND IS READY TO BE INTEGRATED WITH ALL OTHER COMPONENTS REQUIRED FOR A DUAL HORMONE ARTIFICIAL PANCREAS. DURING PHASE IIB, SFC FLUIDICS WILL WORK WITH MANUFACTURERS OF CONTINUOUS GLUCOSE MONITORS, CONTROL ALGORITHMS AND STABLE DRUG FORMULATIONS TO DEVELOP AN FDA-APPROVED, ROBUST, AND RELIABLE DUAL HORMONE ARTIFICIAL PANCREAS.
$115.0k
11/29/22
Not listed
DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR - DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR PROJECT SUMMARY: THE SPECIFIC AIM OF THIS PROJECT IS TO DEVELOP A DISCRETE, LOW-PROFILE, DUAL HORMONE DRUG DELIVERY SYSTEM USING SFC FLUIDICS' ENABLING MICROFLUIDIC TECHNOLOGIES. A DUALPUMP WILL BE DEVELOPED IN WHICH ONE PROPRIETARY EPUMP BODY WILL INDEPENDENTLY AND ACCURATELY DELIVER BOTH INSULIN AND GLUCAGON FROM TWO SEPARATE RESERVOIRS. LATCHING SAFETY VALVE SETS WILL INDEPENDENTLY AND SAFELY CONTROL THE DELIVERY OF EACH HORMONE AND A DISPENSE CONFIRMATION SENSOR WILL NOTIFY THE USER OF ANY DOSING ERRORS RESULTING FROM OCCLUSIONS OR ELECTRICAL/MECHANICAL FAILURES. PHASE II WILL SEE THE INTEGRATION OF ALL COMPONENTS INTO AN ACCURATE, DISCRETE, LOW-PROFILE WEARABLE POD, EXTENSIVE BENCHTOP TESTING AND INITIAL TESTING IN SWINE. THE END GOAL OF PHASE II IS PRODUCTION OF A DUALPUMP MODULE THAT HAS BEEN INTRODUCED TO THE FDA AND IS READY TO BE INTEGRATED WITH ALL OTHER COMPONENTS REQUIRED FOR A DUAL HORMONE ARTIFICIAL PANCREAS. DURING PHASE IIB, SFC FLUIDICS WILL WORK WITH MANUFACTURERS OF CONTINUOUS GLUCOSE MONITORS, CONTROL ALGORITHMS AND STABLE DRUG FORMULATIONS TO DEVELOP AN FDA-APPROVED, ROBUST, AND RELIABLE DUAL HORMONE ARTIFICIAL PANCREAS.
$115.0k
11/29/22
Not listed
DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR - DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR PROJECT SUMMARY: THE SPECIFIC AIM OF THIS PROJECT IS TO DEVELOP A DISCRETE, LOW-PROFILE, DUAL HORMONE DRUG DELIVERY SYSTEM USING SFC FLUIDICS' ENABLING MICROFLUIDIC TECHNOLOGIES. A DUALPUMP WILL BE DEVELOPED IN WHICH ONE PROPRIETARY EPUMP BODY WILL INDEPENDENTLY AND ACCURATELY DELIVER BOTH INSULIN AND GLUCAGON FROM TWO SEPARATE RESERVOIRS. LATCHING SAFETY VALVE SETS WILL INDEPENDENTLY AND SAFELY CONTROL THE DELIVERY OF EACH HORMONE AND A DISPENSE CONFIRMATION SENSOR WILL NOTIFY THE USER OF ANY DOSING ERRORS RESULTING FROM OCCLUSIONS OR ELECTRICAL/MECHANICAL FAILURES. PHASE II WILL SEE THE INTEGRATION OF ALL COMPONENTS INTO AN ACCURATE, DISCRETE, LOW-PROFILE WEARABLE POD, EXTENSIVE BENCHTOP TESTING AND INITIAL TESTING IN SWINE. THE END GOAL OF PHASE II IS PRODUCTION OF A DUALPUMP MODULE THAT HAS BEEN INTRODUCED TO THE FDA AND IS READY TO BE INTEGRATED WITH ALL OTHER COMPONENTS REQUIRED FOR A DUAL HORMONE ARTIFICIAL PANCREAS. DURING PHASE IIB, SFC FLUIDICS WILL WORK WITH MANUFACTURERS OF CONTINUOUS GLUCOSE MONITORS, CONTROL ALGORITHMS AND STABLE DRUG FORMULATIONS TO DEVELOP AN FDA-APPROVED, ROBUST, AND RELIABLE DUAL HORMONE ARTIFICIAL PANCREAS.
($115k)
12/1/21
Not listed
DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR - DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR PROJECT SUMMARY: THE SPECIFIC AIM OF THIS PROJECT IS TO DEVELOP A DISCRETE, LOW-PROFILE, DUAL HORMONE DRUG DELIVERY SYSTEM USING SFC FLUIDICS' ENABLING MICROFLUIDIC TECHNOLOGIES. A DUALPUMP WILL BE DEVELOPED IN WHICH ONE PROPRIETARY EPUMP BODY WILL INDEPENDENTLY AND ACCURATELY DELIVER BOTH INSULIN AND GLUCAGON FROM TWO SEPARATE RESERVOIRS. LATCHING SAFETY VALVE SETS WILL INDEPENDENTLY AND SAFELY CONTROL THE DELIVERY OF EACH HORMONE AND A DISPENSE CONFIRMATION SENSOR WILL NOTIFY THE USER OF ANY DOSING ERRORS RESULTING FROM OCCLUSIONS OR ELECTRICAL/MECHANICAL FAILURES. PHASE II WILL SEE THE INTEGRATION OF ALL COMPONENTS INTO AN ACCURATE, DISCRETE, LOW-PROFILE WEARABLE POD, EXTENSIVE BENCHTOP TESTING AND INITIAL TESTING IN SWINE. THE END GOAL OF PHASE II IS PRODUCTION OF A DUALPUMP MODULE THAT HAS BEEN INTRODUCED TO THE FDA AND IS READY TO BE INTEGRATED WITH ALL OTHER COMPONENTS REQUIRED FOR A DUAL HORMONE ARTIFICIAL PANCREAS. DURING PHASE IIB, SFC FLUIDICS WILL WORK WITH MANUFACTURERS OF CONTINUOUS GLUCOSE MONITORS, CONTROL ALGORITHMS AND STABLE DRUG FORMULATIONS TO DEVELOP AN FDA-APPROVED, ROBUST, AND RELIABLE DUAL HORMONE ARTIFICIAL PANCREAS.
($115k)
12/1/21
Not listed
DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR - DEVELOPMENT OF A LOW-PROFILE DUAL HORMONE PATCH PUMP WITH NOVEL OCCLUSION SENSOR PROJECT SUMMARY: THE SPECIFIC AIM OF THIS PROJECT IS TO DEVELOP A DISCRETE, LOW-PROFILE, DUAL HORMONE DRUG DELIVERY SYSTEM USING SFC FLUIDICS' ENABLING MICROFLUIDIC TECHNOLOGIES. A DUALPUMP WILL BE DEVELOPED IN WHICH ONE PROPRIETARY EPUMP BODY WILL INDEPENDENTLY AND ACCURATELY DELIVER BOTH INSULIN AND GLUCAGON FROM TWO SEPARATE RESERVOIRS. LATCHING SAFETY VALVE SETS WILL INDEPENDENTLY AND SAFELY CONTROL THE DELIVERY OF EACH HORMONE AND A DISPENSE CONFIRMATION SENSOR WILL NOTIFY THE USER OF ANY DOSING ERRORS RESULTING FROM OCCLUSIONS OR ELECTRICAL/MECHANICAL FAILURES. PHASE II WILL SEE THE INTEGRATION OF ALL COMPONENTS INTO AN ACCURATE, DISCRETE, LOW-PROFILE WEARABLE POD, EXTENSIVE BENCHTOP TESTING AND INITIAL TESTING IN SWINE. THE END GOAL OF PHASE II IS PRODUCTION OF A DUALPUMP MODULE THAT HAS BEEN INTRODUCED TO THE FDA AND IS READY TO BE INTEGRATED WITH ALL OTHER COMPONENTS REQUIRED FOR A DUAL HORMONE ARTIFICIAL PANCREAS. DURING PHASE IIB, SFC FLUIDICS WILL WORK WITH MANUFACTURERS OF CONTINUOUS GLUCOSE MONITORS, CONTROL ALGORITHMS AND STABLE DRUG FORMULATIONS TO DEVELOP AN FDA-APPROVED, ROBUST, AND RELIABLE DUAL HORMONE ARTIFICIAL PANCREAS.
($115k)
12/1/21